LTGO

Latigo Biotherapeutics, Inc.

Healthcare · Biotechnology

15.90$ -4.7% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Income Statement

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Income Statement LTGO
Line item	Q1 25	Q2 25	Q1 26	Q2 26
Revenue	–	–	–	–
Research & Development	–	+22.7%	-23.1%	+20.4%
Selling, General & Administrative	–	-0.1%	+105.7%	-21.0%
Total Operating Expenses	–	+19.7%	-9.0%	+10.1%
Operating Income	–	–	–	–
Interest Expense	–	–	–	–
Pre-Tax Income	–	–	–	–
Net Income	–	–	–	–
EBITDA	–	–	–	–

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.